Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles

References

• Ahlin P, Kristl J, Kristl A, Vrecer F. Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int J Pharm, 2002;239:113–20
   PubMed Web of Science ®Google Scholar
• Aravalli RN. Development of MicroRNA therapeutics for hepatocellular carcinoma. Diagnostics, 2013;3:170–91
   Google Scholar
• Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annual Rev Biochem, 1982;51:531–54
   PubMed Web of Science ®Google Scholar
• Calderini A, Pessine Francisco BT, Franchi Gilberto C, Nowill Alexandre E. Preparation and characterisation of 5-fluorouracil containing PLGA nanospheres coated with chitosan, for drug delivery. Int J Nanotechnol, 2012;9:851–61
   Google Scholar
• Cancer Research UK. 2007. UK cancer incidence statistics by age. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/age/. Accessed September 2007
   Google Scholar
• Cha C, De Matteo RP, Blumgart LH. Surgery and ablative therapy for hepatocellular carcinoma. J Clin Gastroenterol, 2002;35:S130–7
   PubMed Web of Science ®Google Scholar
• Chung JW. Transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatogastroenterology, 1998;45:1236–41
   PubMedGoogle Scholar
• Ciechanover A, Schwartz AL, Harvey FL. The Asialoglycoprotein receptor internalizes and recycles independently of the transferrin and insulin receptors. Cell, 1983;32:267–75
   PubMed Web of Science ®Google Scholar
• Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine, 2011;6:877–95
   PubMed Web of Science ®Google Scholar
• Dutta RK, Sahu S. Development of a novel probe sonication assisted enhanced loading of 5-FU in SPION encapsulated pectin nanocarriers for magnetic targeted drug delivery system. Eur J Pharm Biopharm, 2012;82:58–65
   PubMed Web of Science ®Google Scholar
• Fallon RJ, Schwartz AL. Receptor-mediated endocytosis and targeted drug delivery. Hepatology, 1985;5:899–901
   PubMedGoogle Scholar
• Fry DW, White JC, Goldman ID. Rapid separation of low molecular weight solutes from liposomes without dilution. J Anal Biochem, 1978;90:803–7
   Web of Science ®Google Scholar
• Harris RL, van den Berg CW, Bowen DJ. ASGR1 and ASGR2, the genes that encode the Asialoglycoprotein receptor (ashwell receptor), are expressed in peripheral blood monocytes and show inter individual differences in transcript profile. Mol Biol Int, 2012;2012:1–10
   Google Scholar
• Jeon H, Jeong Y, Jang M, Park Y, Nah J. Effect of solvent on the preparation of surfactant-free poly (DL-lactide-co-glycolide) nanoparticles and norfloxacin release characteristics. Int J Pharm, 2000;207:99–108
   PubMed Web of Science ®Google Scholar
• Kim IS, Kim SH. Development of polymeric nanoparticulate drug delivery systems: Evaluation of nanoparticles based on biotinylated poly (ethylene glycol) with sugar moiety. Int J Pharm, 2003;257:195–203
   PubMed Web of Science ®Google Scholar
• Li L, Wang H, Ong ZY, Xu K, Ee PLR, Zheng S, Hedrick JL, Yang YY. Polymer and lipid based nanoparticle therapeutics for treatment of liver diseases. Nano Today, 2010;5:296–312
   Web of Science ®Google Scholar
• Liang HF, Chen CT, Chen SC, Kulkarni AR, Chiu YL, Chen MC, Sung HW. Paclitaxel-loaded poly (γ-glutamic acid) – Poly (lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials, 2006a;27:2051–9
   PubMed Web of Science ®Google Scholar
• Liang L, Ping J, Ming C, Guoliang Z, Fengbao Z. 5-Fluorouracil – Loaded self assembled pH sensitive nanoparticles as novel drug carrier for treatment of malignant tumors. Chinese J Chem Eng, 2006b;14:377–82
   Google Scholar
• Nassim MA, Shirazi FZ, Cripps CM, Veerasinghan S, Molepo MJ, Obrocea M, Redmond D, Bates S, Fry D, Stewart DJ, Goel R. An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield. Int J Mol Med, 2002;10:513–16
   PubMed Web of Science ®Google Scholar
• Ocal H, Arıca-Yegin B, Vura İ, Goracinova K, Çaliş S. 5-Fluorouracil-loaded PLA/PLGA PEG–PPG–PEG polymeric nanoparticles: Formulation, in vitro characterization and cell culture studies. Drug Dev Ind Pharm, 2013;5:332–41
   Google Scholar
• Park J, Fong PM, Lu J, Russel KS, Booth CJ, Saltzman WM, Fahmy TM. Pegylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine, 2009;5:410–18
   Google Scholar
• Schwartz AL, Friodovlch SE, Knowles BB, Lodish HF. Characterization of the asialoglycoprotein receptor in a continuous hepatoma line. J Biol Chem, 1981;256:8878–81
   PubMed Web of Science ®Google Scholar
• Scott HM, Venkatesh T, Maxim VC, Donna SS, William DE, Mohamed El-Sayed EH. N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers. Biomaterials, 2011;32:4118–29
   PubMedGoogle Scholar
• Sinjan D, Dennis HR. Particle size and temperature effect on the physical stability of PLGA nanospheres and microspheres cotaining bodipy. AAPS PharmSciTech, 2004;5:1–7
   Google Scholar
• Skehn P, Storeng R, Scudiero A, Monks J, McMohan D, Vistica D, Jonathan TW, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst, 1990;82:1107–12
   PubMedGoogle Scholar
• Song KC, Ho SL, Il YC, Kyung IC, Yangkyu A, Eun JC. The effect of type of organic phase solvents on the particle size of poly (d, l-lactide-co-glycolide) nanoparticles. Colloids Surf A: Physicochem Eng Aspects, 2006;276:162–7
   Web of Science ®Google Scholar
• Sturm JW, Keese MA, Bonninghoff RG, Wustner M, Post S. Locally ablative therapies of hepatocellular carcinoma. Oncology, 2001;24:35–45
   Google Scholar
• Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol, 2001;7:445–54
   PubMed Web of Science ®Google Scholar
• Teo EK, Fock KM. Hepatocellular carcinoma: An Asian perspective. Drug Dis, 2001;19:263–8
   Google Scholar
• Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESDO, Eur Soc Digest Oncol Ann Oncol, 2012;23(Supplement 7):vii41–8
   PubMedGoogle Scholar
• Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature Protocol, 2006;1:1112–16
   PubMed Web of Science ®Google Scholar
• Wei S, Yinghui C, Weien Y. Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors. Int J Nanomedicine, 2013;8:1499–506
   PubMedGoogle Scholar
• Zhou X, Zhang M, Yung B, Li H, Zhou C, Lee LJ, Lee RJ. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int J Nanomedicine, 2012;7:5465–74
   PubMed Web of Science ®Google Scholar
• Zhu XL, Du YZ, Yu RS, Liu P, Shi D, Chen Y, Wang Y, Huang FF. Galactosylated chitosan oligosaccharide nanoparticles for hepatocellular carcinoma cell-targeted delivery of adenosine triphosphate int. J Mol Sci, 2013;14:15755–66
   Google Scholar